Clinical trial · Observational
The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer
The Effectiveness of 18F-fluorocholine PET in Detecting, Staging and Following-up Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Choline is one of the components of phosphatidylcholine, an essential element of phospholipids in the cell membrane. Some malignant cells show their ability to actively incorporate choline to produce phosphocholine and phosphatidylcholine to facilitate tumor cell duplication. The efficacy of 18F-fluorocholine (18F-FCH) for localizing primary or metastatic prostate cancer has been recently reported in limited studies. This study will be conducted to delineate the effectiveness of 18F-FCH PET in (1) differentiating benign prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate cancer, (3) following-up patients with prostate cancer after initial curative therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Group 1
- description
- patients with BPH
- label
- Group 2
- description
- patients with newly diagnosed prostate cancer
- label
- Group 3
- description
- patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 35 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Group 1: 50 patients with BPH 1. Age above 35 years old 2. Histologically confirmed BPH 3. Informed consent signed Group 2: 50 patients with newly diagnosed prostate cancer and 1. Age above 35 years old 2. Histologically confirmed prostate cancer 3. Informed consent signed Group 3: 50 patients who have 1. Age above 35 years old 2. Histologically confirmed prostate cancer and had received curative treatment for prostate cancer 3. suspicious of recurrence/metastases because of a persistent increase in their serum PSA 4. Informed consent signed Exclusion Criteria: * Patients with other known malignancies will be excluded.
References
Publications (0)
Data not yet available